Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Axonics, Inc.
  6. News
  7. Summary
    AXNX   US05465P1012

AXONICS, INC.

(AXNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Needham Adjusts Price Target on Axonics to $71 From $78, Maintains Buy Rating

11/05/2021 | 11:36am EST


© MT Newswires 2021
All news about AXONICS, INC.
01/06AXONICS : reg; Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue - Form 8-K
PU
01/06AXONICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/06Axonics Increases Q4, Full-year 2021 Revenue Guidance
MT
01/06Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
BU
01/06Axonics, Inc. Provides Earning Guidance for the Fourth Quarter and Fiscal Year of 2021
CI
2021Needham Cuts Axonics' Price Target to $62 From $71, Citing CPT Code Change Impacting Sa..
MT
2021Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by th..
BU
2021Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Techn..
BU
2021Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
BU
2021Needham Adjusts Price Target on Axonics to $71 From $78, Maintains Buy Rating
MT
More news
Analyst Recommendations on AXONICS, INC.
More recommendations
Financials (USD)
Sales 2021 179 M - -
Net income 2021 -80,4 M - -
Net cash 2021 206 M - -
P/E ratio 2021 -28,5x
Yield 2021 -
Capitalization 2 494 M 2 494 M -
EV / Sales 2021 12,8x
EV / Sales 2022 10,0x
Nbr of Employees 416
Free-Float -
Chart AXONICS, INC.
Duration : Period :
Axonics, Inc. Technical Analysis Chart | AXNX | US05465P1012 | MarketScreener
Technical analysis trends AXONICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 53,86 $
Average target price 75,88 $
Spread / Average Target 40,9%
EPS Revisions
Managers and Directors
Raymond Wayne Cohen Chief Executive Officer & Director
Danny L. Dearen President & Chief Financial Officer
Michael H. Carrel Chairman
Guang Qiang Jiang Chief Technology Officer
Karen Noblett Chief Medical Officer
Sector and Competitors